Perceptive Advisors LLC Acquires New Shares in Invivyd, Inc. $IVVD

Perceptive Advisors LLC acquired a new stake in Invivyd, Inc. (NASDAQ:IVVD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,785,166 shares of the company’s stock, valued at approximately $53,809,000. Perceptive Advisors LLC owned about 9.35% of Invivyd as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in IVVD. GSA Capital Partners LLP increased its position in shares of Invivyd by 85.0% during the third quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock worth $886,000 after acquiring an additional 369,891 shares during the period. Eventide Asset Management LLC purchased a new stake in shares of Invivyd during the fourth quarter worth $14,349,000. UBS Group AG increased its position in shares of Invivyd by 683.8% during the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after acquiring an additional 916,842 shares during the period. BVF Inc. IL purchased a new stake in shares of Invivyd during the fourth quarter worth $48,227,000. Finally, State of Wyoming purchased a new position in Invivyd in the fourth quarter valued at $30,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Up 4.4%

Shares of NASDAQ:IVVD opened at $0.93 on Thursday. The company has a market cap of $274.34 million, a P/E ratio of -3.00 and a beta of 0.63. Invivyd, Inc. has a 52 week low of $0.48 and a 52 week high of $3.07. The company has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.74.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. Analysts expect that Invivyd, Inc. will post -0.5 EPS for the current year.

Analyst Ratings Changes

IVVD has been the subject of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research report on Tuesday, June 9th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. Finally, Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.